Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Claus

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Antibodies (Basel, Switzerland)|November 24, 2025
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCBChristina Claus, Claudia Ferrara-Koller, Johannes Sam, et al.
Mabs|December 16, 2025
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapyMarlena Surowka, Diana Darowski, Idil Hutter-Karakoc, et al.
Journal for Immunotherapy of Cancer|February 11, 2025
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor modelsEneko Garate-Soraluze, Irantzu Serrano-Mendioroz, Leticia Fernández-Rubio, et al.
Nature Medicine|February 9, 2010
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunityLukas Flatz, Ahmed N Hegazy, Andreas Bergthaler, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancerMarta Trüb, Franziska Uhlenbrock, Christina Claus, et al.
The Journal of Clinical Investigation|May 23, 2023
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphomaBenedetta Apollonio, Filomena Spada, Nedyalko Petrov, et al.
Cancer Research|May 16, 2020
The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody TreatmentChristoph M Griessinger, Tove Olafsen, Alessandro Mascioni, et al.
Blood|March 4, 2024
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapyJohannes Sam, Thomas Hofer, Christine Kuettel, et al.
Science Translational Medicine|June 14, 2019
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapyChristina Claus, Claudia Ferrara, Wei Xu, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Antibodies (Basel, Switzerland)|November 24, 2025
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCBChristina Claus, Claudia Ferrara-Koller, Johannes Sam, et al.
Mabs|December 16, 2025
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapyMarlena Surowka, Diana Darowski, Idil Hutter-Karakoc, et al.
Journal for Immunotherapy of Cancer|February 11, 2025
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor modelsEneko Garate-Soraluze, Irantzu Serrano-Mendioroz, Leticia Fernández-Rubio, et al.
Nature Medicine|February 9, 2010
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunityLukas Flatz, Ahmed N Hegazy, Andreas Bergthaler, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancerMarta Trüb, Franziska Uhlenbrock, Christina Claus, et al.
The Journal of Clinical Investigation|May 23, 2023
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphomaBenedetta Apollonio, Filomena Spada, Nedyalko Petrov, et al.
Cancer Research|May 16, 2020
The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody TreatmentChristoph M Griessinger, Tove Olafsen, Alessandro Mascioni, et al.
Blood|March 4, 2024
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapyJohannes Sam, Thomas Hofer, Christine Kuettel, et al.
Science Translational Medicine|June 14, 2019
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapyChristina Claus, Claudia Ferrara, Wei Xu, et al.
Pageof 2